John Patton

John Patton is a prominent figure in the pharmaceutical and biotech industry with extensive experience in drug delivery and inhalation technologies. Here are some key details about his background and career:

Professional Experience

• Executive Chairman and Co-Founder of iPharma Labs, a contract development research organization focused on inhalation delivery products.24

• Founder, former CEO, and former Chairman of Aerami Therapeutics (previously Dance Biopharm), which developed inhaled insulin solutions.34

• Co-founder of Inhale/Nektar Therapeutics in 1990, where he served in various roles including Vice President of Research, Chief Scientific Officer, and board member until 2008.34

• Founding investor and board member of Halozyme Therapeutics from 1999 to 2015.23

• Co-founder and Executive Chairman of InCarda Therapeutics, focusing on inhaled medicines for acute cardiac conditions.24

• CEO and Chairman of Tesio Pharmaceuticals since October 2019.4

Scientific Contributions

• Pioneer in the development of inhaled drugs, with over 100 publications and more than 45 patents.2

• Led the drug delivery team at Genentech from 1985 to 1990.13

• Contributed to the development of Exubera, the first FDA-approved inhaled insulin, which received the Wall Street Journal's Medical Innovation of the Year award in 2006.12

Education

• B.S. in Zoology from Pennsylvania State University
• M.S. in Biochemistry from the University of Rhode Island
• Ph.D. in Biology from the University of California, San Diego34

John Patton has served on numerous scientific advisory boards and has been involved in multiple successful biotech ventures throughout his career. His expertise in drug delivery science, particularly in inhalation technologies, has made him a respected figure in the pharmaceutical industry.